

## References

I-79

1. Mozobil (plerixafor)[Prescribing Information]. Cambridge, MA:Genzyme Corporation;2010.
2. Brave M, Farrell A, Ching Lin S, et al. FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation. *Oncology*. 2010;78(3-4):282-8.
3. Flomenberg N, Comenzo RL, Badel K, Calandra G. Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation. *Biol Blood Marrow Transplant*. 2010;16(5):695-700.
4. Fruehauf S, Ehninger G, Hübel K, et al. Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients. *Bone Marrow Transplant*. 2010;45(2):269-275.
5. Shaughnessy P, Islas-Ohlmayer M, Murphy J, et al. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide. *Biol Blood Marrow Transplant*. 2011;17(5):729-736.
6. Tanhehco YC, Vogl DT, Stadtmauer EA, et al. The evolving role of plerixafor in hematopoietic progenitor cell mobilization. *Transfusion*. 2013 Jan 30.
7. Maziarz RT, Nademanee AP, Micallef IN. et al. Plerixafor Plus Granulocyte Colony-Stimulating Factor Improves the Mobilization of Hematopoietic Stem Cells in Patients with Non-Hodgkin Lymphoma and Low Circulating Peripheral Blood CD34(+) Cells. *Biol Blood Marrow Transplant*. 2013 Jan 17.
8. Shaughnessy P, Uberti J, Devine S. et al. Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin's lymphoma and multiple myeloma: results from the expanded access program. *Bone Marrow Transplant*. 2012 Nov 26.
9. Milone G, Tripepi G, Martino M, et al. Early measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilization failure and is a possible criterion for guiding "on demand" use of plerixafor. *Blood Transfus*. 2013 Jan;11:94-101.
10. Russell N, Douglas K, Ho AD, Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial. *Haematologica*. 2013 Feb;98(2):172-8.
11. Mozobil (plerixafor) [Prescribing Information]. Genzyme Corporation. Cambridge:MA. December 2008. Revised April 2010.
12. AHFS drug information. 2012 ed. Bethesda (MD): American Society of Healthy Systems Pharmacists; 2012: 1602-1603.
13. Choi W, Duggineni S, Xu Y, et al. Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4). *J Med Chem*. 2012;55(3):977-994.
14. Negrin R. Sources of hematopoietic stem cells. *UpToDate*. 2013 May.

15. Fruehauf S. Current clinical indications for plerixafor. *Transfus Med Hemother*. 2013;40:246-250.
16. Lanza F, Lemoli R, Bosi A, et al. Factors affecting successful mobilization with plerixafor: An Italian prospective survey in 215 patients with multiple myeloma and lymphoma. *Transfusion*. 2014 Feb;54(2):331-9.
17. Abdel-Rahman F, Tuffaha H, Hussein A, et al. GCSF with or without chemotherapy compared to Plerixafor with GCSF as salvage mobilization regimen in patients with multiple myeloma and lymphoma: Collection effectiveness and cost effectiveness analysis. *J Oncol Pharm Pract*. 2014 Apr;20(2):130-6.
18. Hübel K, Fresen MM, Apperley JF. et al. European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization. *Bone Marrow Transplant*. 2012 Aug;47(8):1046-50.
19. McDermott D, Liu Q, Velez D, et al. A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor. *Blood*. 2014;123(15):2308-16.
20. Dhakal B, Strouse C, D'Souza A, et al. Plerixafor and abbreviated-course granulocyte colony-stimulating factor for mobilizing hematopoietic progenitor cells in light chain amyloidosis. *Biol Blood Marrow Transplant*. 2014;20(12):1926-31.
21. Pantin J, Purev E, Tian X et al. Effect of high-dose plerixafor on CD34+ cell mobilization in healthy stem cell donors: results of a randomized crossover trial. *Haematologica*. 2017;600-609.
22. Goker H, Etkul S, Buyukasik Y. Optimizing mobilization strategies in difficult-to-mobilize patients: The role of plerixafor. *Transfusion and Apheresis Science*. 2015;23-29.
23. MICROMEDEX®SOLUTIONS Compendia. 2017.
24. NCCN Drugs & Biologics Compendium™. Plerixafor. 2017. National Comprehensive Cancer Network (NCCN).
25. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Plerixafor\_